Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G)
Not Applicable
- Conditions
- BRAF V600E-mutant Metastatic Colorectal Cancer
- Registration Number
- JPRN-UMIN000041098
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients with another concomitant cancer at the time of diagnosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method